Treasury Proposal Spares China Biotech Licensing Deals — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Treasury Department proposed a rule last week to limit U.S. investment in the Chinese biotech industry.
- U.S. biotech players have argued over whether restrictions are needed, weighing an offensive strategy of boosting domestic research and development against a defensive one of preventing Chinese biotechs from catching up.
- Proposed rule is more aggressive than some anticipated, and the debate has now shifted from whether to restrict investment to what the restriction would do.
- Licensing deals are exempt according to a Treasury official, and that carve-out is at the heart of current disagreements over the proposal's effects.
Why it matters: Treasury's more aggressive proposal, advanced last week, puts two competing strategies in play: boost U.S. research and development or prevent Chinese biotechs from catching up. For U.S. policymakers, the licensing carve-out keeps a separate deal channel open, making the exemption the material divide in the rule's effects.
Ask SkimNews
